EMA Authorised: Xeloda (capecitabine) — CHEPLAPHARM Arzneimittel GmbH

View source ↗

Summary

The EMA authorised CHEPLAPHARM Arzneimittel GmbH to market Xeloda (capecitabine) in the EU for several cancers, including breast, colon/colorectal, and gastric …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colon Cancer
• Colorectal Cancer
• Gastric Cancer

Drugs mentioned

• Xeloda (capecitabine)

Snippet

Status: Authorised. Therapeutic area: Colonic Neoplasms;Breast Neoplasms;Colorectal Neoplasms;Stomach Neoplasms. MAH: CHEPLAPHARM Arzneimittel GmbH. Decision date: 28/03/2025